Kidney Cancer Treatment in Turkey: How Partial Nephrectomy, Robotic Surgery and Ablation Are Chosen

Kidney Cancer Treatment Options in Turkey

Every treatment decision follows from two numbers: the size of the tumour and whether it has left the kidney. Tumours up to 7 cm still inside the kidney are treated by removing the tumour and keeping the kidney. Larger or central tumours usually need the whole kidney. Disease that has spread is treated with drugs rather than surgery.

What Is Kidney Cancer?

About 90 percent of kidney cancers are renal cell carcinoma, which starts in the small tubes that filter blood. Roughly 75 percent are clear cell, 10 to 15 percent papillary and about 5 percent chromophobe. The type matters: clear cell disease responds to immunotherapy, while chromophobe tumours behave far less aggressively.

Each kidney filters around 180 litres of blood a day and also controls blood pressure. That is why modern surgery aims to remove the tumour while leaving as much working kidney as possible.

Symptoms and Risk Factors

Kidney cancer is mostly silent, which explains how it is found. Between 50 and 60 percent of cases are discovered by accident on imaging ordered for something else. The classic triad of flank pain, blood in the urine and a palpable lump appears in fewer than 10 percent of patients, and by then the disease is usually advanced.

It also produces systemic effects that can arrive before any local sign: weight loss, low fever, night sweats, anaemia, a high calcium level and new high blood pressure. These occur in about 20 percent of patients.

Smoking roughly doubles the risk and accounts for an estimated 30 percent of cases in men. Obesity follows, with risk rising about 24 percent in men and 34 percent in women for every 5 unit increase in body mass index, then high blood pressure and chronic kidney disease. The SEER programme of the United States National Cancer Institute puts the median age at diagnosis at 65.

Diagnosis and Staging

Kidney cancer is one of the few cancers usually diagnosed without a biopsy. A contrast enhanced CT scan is accurate enough that surgery is planned from the imaging alone, with reported accuracy above 90 percent for solid enhancing masses. Biopsy is reserved for cases where ablation or surveillance is being considered.

The T category decides between keeping the kidney and removing it.

Partial Nephrectomy, Kidney Sparing Surgery

Partial nephrectomy removes the tumour with a thin rim of healthy tissue and leaves the rest of the kidney in place. It is the reference treatment for T1 disease, up to 7 cm.

The reason is not cosmetic. Removing a whole kidney raises the long term risk of chronic kidney disease. In patients with a normal opposite kidney, it is reported in around 65 percent after radical nephrectomy against about 20 percent after partial nephrectomy. Cancer control is equivalent for T1 tumours, with 5 year cancer specific survival above 95 percent for both.

Blood flow is briefly clamped during the operation. Warm ischaemia under 25 minutes preserves kidney function better, and robotic assistance shortens it.

Radical Nephrectomy

Radical nephrectomy removes the whole kidney with the surrounding fat inside Gerota fascia. It remains the right operation for tumours over 7 cm, for central tumours that cannot be separated from the collecting system, and for disease extending into the renal vein or vena cava.

Two things once routine are now avoided. The adrenal gland is left in place unless it looks involved, and extended lymph node dissection is not performed for its own sake, because trials showed no survival benefit in node negative disease. Afterwards the remaining kidney takes on most of the filtering load.

Robotic Kidney Surgery

Compared with open surgery, published series report blood loss lower by roughly 100 to 150 millilitres, hospital stay shortened from about 6 days to 2 to 4 days, and return to normal activity in 2 to 3 weeks rather than 6, with equivalent cancer outcomes. Against laparoscopy it achieves shorter warm ischaemia and preserves the kidney more often in complex tumours.

Ablation and Active Surveillance

Not every small kidney tumour needs an operation. Cryoablation freezes the tumour and radiofrequency ablation heats it, both through a needle under the skin, usually as a day case. They suit tumours under 3 cm in patients who are elderly, have a single kidney or carry surgical risk. Local recurrence is higher than after surgery, around 5 to 10 percent against 1 to 2 percent.

Active surveillance is the other option. Small renal masses grow at an average of 2 to 3 millimetres a year, and the risk of metastasis below 3 cm is close to 1 percent. It means a scan every 3 to 6 months, with treatment triggered by growth beyond 4 cm or above 5 millimetres a year.

Advanced and Metastatic Disease

Roughly 16 percent of kidney cancers have already spread when found, most often to the lungs, bones, liver or brain. Conventional chemotherapy has almost no effect on renal cell carcinoma, which is why treatment here looks so different.

First line treatment pairs a checkpoint immunotherapy drug such as nivolumab or pembrolizumab with either a second immunotherapy or a tyrosine kinase inhibitor such as cabozantinib. Modern combinations report objective response rates of 55 to 70 percent, against about 25 percent for targeted therapy alone a decade ago. Surgery still has a role: removing the primary tumour or a solitary metastasis can give long periods free of treatment.

Why Patients Travel to Turkey for Treatment

According to the Turkish Statistical Institute, about 1.5 million people travelled to Turkey for medical treatment in 2023, and Turkey has one of the largest groups of hospitals outside the United States accredited by Joint Commission International.

For American patients the driver is cost: the same operation, with the same da Vinci systems, for a fraction of the American price. For Canadians it is time, since the Fraser Institute's annual survey has put the median wait from referral to treatment at around 27 weeks. European patients come for a three to four hour flight and because Turkish urology works to European Association of Urology guidelines, so the plan transfers home without argument.

Survival Outcomes and Follow up

The figures below come from the SEER programme of the United States National Cancer Institute. They are population averages, not a prediction for any individual.

Follow up is set by the risk of the tumour removed: low risk disease is scanned at 6 months then yearly to year 5, higher risk every 3 to 6 months for 3 years. About 20 to 30 percent of patients treated for localised disease relapse, most within the first 3 years, and the lungs are the commonest site. Follow up can be shared with your own urologist at home.

Frequently Asked Questions